5,100 Shares in Gilead Sciences, Inc. $GILD Bought by Notis McConarty Edward

Notis McConarty Edward purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 5,100 shares of the biopharmaceutical company’s stock, valued at approximately $644,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth about $15,393,785,000. Norges Bank bought a new position in shares of Gilead Sciences during the fourth quarter worth about $2,617,152,000. Deutsche Bank AG bought a new position in shares of Gilead Sciences during the second quarter worth about $918,387,000. Boston Partners acquired a new position in Gilead Sciences in the fourth quarter worth about $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Gilead Sciences in the second quarter worth about $398,905,000. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the transaction, the insider directly owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock valued at $10,837,860 over the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $147.60 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a 50 day moving average of $131.21 and a two-hundred day moving average of $136.51. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a market cap of $183.02 billion, a P/E ratio of -55.28 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.01 earnings per share. As a group, analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Weiss Ratings cut Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Royal Bank Of Canada lifted their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Barclays dropped their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.